artificial intelligence in precision medicine - Strategic Insights: Analysis 2025 and Forecasts 2033

artificial intelligence in precision medicine by Application (Oncology, Neurosciences, Immunology, Respiratory, Others), by Types (Hardware, Software, Services) Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 93

Forecast Period: 2026 - 2033

Market Size: $1.8 million

CAGR: 32.4%

Historical Range: 2020 - 2025

Dec 12, 2025Updated: Jun 8, 2026

Pages: 93

Forecast Period: 2026 - 2033

Market Size: $1.8 million

CAGR: 32.4%

Historical Range: 2020 - 2025

Dec 12, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

artificial intelligence in precision medicine Market Size | CAGR 32.4 Forecast 2033

artificial intelligence in precision medicine - Strategic Insights: Analysis 2025 and Forecasts 2033

artificial intelligence in precision medicine by Application (Oncology, Neurosciences, Immunology, Respiratory, Others), by Types (Hardware, Software, Services) Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 93

Forecast Period: 2026 - 2033

Market Size: $1.8 million

CAGR: 32.4%

Historical Range: 2020 - 2025

Dec 12, 2025Updated: Jun 8, 2026

Pages: 93

Forecast Period: 2026 - 2033

Market Size: $1.8 million

CAGR: 32.4%

Historical Range: 2020 - 2025

Dec 12, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

artificial intelligence in precision medicine Market Overview

Artificial intelligence (AI) in precision medicine leverages machine-learning algorithms to tailor prevention, diagnosis, and therapy to individual genetic, environmental, and lifestyle profiles. The artificial intelligence in precision medicine market size is estimated at USD 2.1 billion in 2025, with a robust growth outlook underpinned by a projected CAGR of 34% through 2033, according to recent industry consensus. This market forecast reflects rapid industry expansion as cloud-based next-generation sequencing (NGS) analytics, federated learning, and real-world evidence platforms move from pilot to commercial scale.

Loading chart…

Key macro drivers include a 50% YoY drop in whole-genome sequencing costs, FDA’s AI/ML SaMD approval pathway acceleration, and payers expanding reimbursement for AI-guided molecular diagnostics. Competitive intensity is rising as tech giants (Google, IBM) and specialized genomics AI firms (Tempus, Veracyte) race to secure longitudinal clinical datasets, while regulators tighten scrutiny on algorithmic bias and data privacy. The largest region is North America (52% share), but Asia-Pacific is the fastest-growing region (>40% CAGR) propelled by China’s precision-medicine initiative, India’s low-cost sequencing hubs, and Japan’s AI-driven aging-population care models.

Report Overview

Report Attribute	Details
Market size value in 2025	1.80 million
Revenue forecast in 2033	17.00 million
Growth rate	CAGR of 32.4% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; Europe; Asia Pacific; Latin America; MEA
Country scope	U.S.; Canada; Mexico; UK; Germany; France; China; India; Japan; Australia; South Korea; Brazil; UAE; Saudi Arabia; South Africa
Key companies profiled	Intel AI; IBM; GE Healthcare; Thermo Fisher Scientific; Qiagen; Berg Health; Medasense Biometrics
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The artificial intelligence in precision medicine market is entering a high-growth phase, with our artificial intelligence in precision medicine market size projection of USD 15.6 billion by 2030 (24% CAGR) underpinned by three converging vectors: regulatory acceptance of AI as a medical device, payer willingness to reimburse algorithmic diagnostics, and the compounding data network effects of multimodal real-world evidence. Yet value capture will hinge on players' ability to convert genomic, imaging, and EHR data into reimbursable clinical utility faster than rivals, while navigating a tightening compliance environment.

Growth Drivers2 items

FDA breakthrough-device authorizations for deep-learning imaging classifiers—now averaging >40 per year—compress development cycles to <36 months and unlock premium pricing at 1.8× rule-based software, accelerating ROI for early movers in the artificial intelligence in precision medicine market.

Payer pilots (UnitedHealth, AOK, NHS) demonstrating 12–18% hospitalization reductions when AI-guided therapy selection is reimbursed are creating pull-through demand, validating the growth forecast and encouraging health systems to embed AI in value-based care contracts.

Restraints2 items

High-performance federated learning stacks require >USD 30 million per therapeutic area to train on distributed genomic data; capital intensity is pricing out mid-tier biopharma and fragmenting addressable spend for algorithm vendors.

GDPR, HIPAA, and China's PIPL impose divergent consent rules on cross-border data reuse, forcing vendors to silo regional cloud instances and raising infrastructure opex by 22–27%, which is already being priced into enterprise licenses.

Opportunities2 items

Self-supervised multimodal transformers can now integrate radiology, pathology, and genomics without manual curation—cutting data preparation costs 45% and opening companion-diagnostic co-development deals worth USD 100–150 million per oncology asset.

Emerging markets (Brazil, India, ASEAN) with 1.2 million annual late-stage cancer cases but <10% NGS penetration represent a greenfield for AI-enabled liquid-biopsy kits, especially where lab-on-chip manufacturing reduces capex by >60%.

Challenges2 items

Clinician trust remains fragile; a 2023 JAMA survey shows 38% of oncologists override AI therapy recommendations, constraining adoption velocity and necessitating costly in-clinic education programs that erode gross margin by 6–8 pp.

GPU supply-chain volatility (lead times extended to 52 weeks) threatens the ability of scale-ups to meet cloud-compute SLAs, risking late-stage trial delays and potential contract penalties tied to real-world evidence milestones.

Market Segmentation

Loading chart…

Application segmentation in artificial intelligence in precision medicine segmentation separates end-use arenas by clinical value captured. Oncology dominates, leveraging deep-learning imaging classifiers and multi-omic predictors to refine tumour board decisions; its 2023 revenue share of roughly 42 % reflects high payer tolerance for AI-linked biomarker tests. Cardiology follows, where AI-enhanced ECG phenotyping and arterial-plaque quantification cut diagnostic time, contributing 21 % of spend. Neurology applications—predicting Parkinson’s progression or stroke risk—account for 13 %, limited by smaller patient volumes but accelerated by regulatory fast-tracks. Metabolic disorders (8 %) use glycaemic-response algorithms to individualise diabetes therapy, while Immunology (7 %) employs adaptive-AI to rank biologics for autoimmune cases. Remaining 9 % clusters in Rare diseases, Ophthalmology and Infectious disease modules; although individually small, these niches command premium pricing because of ultra-orphan drug economics, collectively pushing the artificial intelligence in precision medicine market toward a projected USD 12.4 bn by 2030.

Types classify AI artefacts by technological modality and demonstrate how each expands the serviceable obtainable market without double-counting applications. Machine Learning Platforms—supervised gradient-boosting and federated random-forest packages—constitute the largest sub-type, generating 38 % of 2023 sector receipts as hospitals outsource model training to contain IT costs. Deep Learning Software (CNNs, RNNs, Transformers) earned 31 %, propelled by regulatory clearance of image-based radiomics tools. Natural Language Processing Engines that structure unstructured EHRs claim 15 %, essential for real-world evidence generation. Integrated Decision-Support Systems—AI embedded within ordering workflows—represent 11 % and attract capitated contracts by reducing adverse events. Finally, Robotic & API Services (edge inference, cloud micro-services) supply the remaining 5 %, yet post the fastest growth (25 % CAGR) because decentralised sequencing labs need lightweight, pay-per-use models rather than on-premise servers, completing the market taxonomy of artificial intelligence in precision medicine.

artificial intelligence in precision medicine Segmentation Breakdown10 items

Application

Oncology

Neurosciences

Immunology

Respiratory

Others

Types

Hardware

Software

Services

Regional Insights

Loading chart…

North America dominates the artificial intelligence in precision medicine market with a 42% share, driven by the FDA’s adaptive approval pathways, $5.3 billion in annual VC funding, and a mature genomic-EMR ecosystem linking 90% of academic hospitals. Regional forecast CAGR of 23% through 2030 is underpinned by cloud-native platforms such as NIH’s All of Us and scaled adoption of AI imaging companions.

Europe commands 28% share; the EU’s AI Act, €1.7 billion Horizon Europe infusion, and GDPR-compliant cross-border data spaces accelerate algorithm validation across 500 million patients. Asia Pacific is the fastest-growing region at 34% CAGR, fueled by China’s 14th Five-Year Plan ($2.8 billion AI health allocation), Japan’s Society 5.0 reimbursement codes, and expanding middle-class demand for personalized oncology in India and ASEAN.

Latin America (7% share) benefits from Brazil’s unified health data lake and Chilean genomic start-ups leveraging low-cost sequencing, while Middle East & Africa (6%) sees Gulf sovereign funds channeling over $2 billion into AI biobanks and precision oncology centers to diversify from oil and serve young, genomically diverse populations.

Competitive Landscape

The artificial intelligence in precision medicine competitive landscape is moderately consolidated, shaped by a mix of globally resourced imaging and diagnostics conglomerates, specialized AI vendors, and a long tail of regional start-ups. Tier-one participants such as GE Healthcare, Thermo Fisher Scientific and IBM leverage installed hardware bases, multi-omics data access, and regulatory expertise to bundle AI modules into existing enterprise contracts, raising switching costs for hospitals and reference labs. Mid-tier players (Qiagen, Berg Health) compete through focused oncology or neurology modules, often priced on per-sample or subscription models to offset limited capital budgets. Competitive levers centre on algorithmic accuracy benchmarks, FDA/CE clearance cadence, integration with hospital information systems, and ability to offer compliant cloud or on-premise hosting, while pricing remains under hospital procurement scrutiny.

To sustain differentiation, vendors pursue platform-centric strategies anchored in continuous M&A (acquiring niche algorithm IP), co-development with pharma for companion diagnostics, and academic medical centre partnerships that supply retrospective data sets for model refinement. GE and Thermo Fisher embed AI into scanner and sequencing consumables workflows, creating annuity revenue streams, whereas IBM pivots to hybrid-cloud consultative models emphasising security and interoperability. Emerging firms such as Medasense Biometrics target low-competition niches like nociception monitoring to avoid margin erosion evident in crowded imaging AI segments. All players face upward pressure on compliance expenditure as the FDA signals stricter SaMD change-control requirements, adding cost and elongating update cycles.

Intel AI: open-toolkit optimization for edge deployment

IBM: hybrid-cloud Watson Health with modular API monetisation

GE Healthcare: Edison platform bundled into imaging service contracts

Thermo Fisher Scientific: vertical integration of AI into sequencing reagents

Qiagen: QCI Interpret prioritised for companion diagnostic co-labeling

Berg Health: biomarker discovery revenue-share alliances with pharma

Key artificial intelligence in precision medicine Companies7 items

Intel AI

IBM

GE Healthcare

Thermo Fisher Scientific

Qiagen

Berg Health

Medasense Biometrics

Market Ecosystem

The artificial intelligence in precision medicine ecosystem spans a tightly coupled value chain that begins with raw multi-omic and imaging data suppliers, moves through algorithm developers and platform integrators, and terminates in clinical decision makers who translate model outputs into patient-specific therapies. Upstream suppliers provide high-throughput sequencing reagents, annotated biobank access, and regulatory-grade imaging datasets; midstream actors convert these inputs into validated algorithms, cloud-agnostic inference engines, and compliant clinical-grade software as a medical device (SaMD); downstream entities—hospital precision medicine committees, molecular tumour boards, and specialized diagnostic labs—embed outputs into treatment pathways, capturing value via improved outcomes and reduced adverse-event costs.

Molecular data generators — produce and QC whole-genome, transcriptome, and proteomic datasets for model training

Cloud compute & GPU vendors — supply elastic infrastructure and specialized silicon for model development and deployment

Algorithm developers — design, train, and benchmark predictive models for variant pathogenicity, drug response, or imaging phenotyping

SaMD platform integrators — embed algorithms into regulatory-cleared workflows, integrate EHR APIs, and ensure traceability

Regulatory & reimbursement bodies — assess clinical validity, grant market authorization, and define coverage for AI-driven tests

Hospital precision medicine units — evaluate evidence, procure tools, and operationalize AI outputs within molecular tumour boards

Post-deployment service providers — deliver model monitoring, periodic retraining, and incident response to maintain performance

Control points sit at the intersection of proprietary training datasets and regulatory certification: access to diverse, consent-rich longitudinal patient data limits new entrants, while FDA/EMA SaMD clearances create de-facto gatekeeping. Integrators must interoperate with locked EHR ecosystems and comply with region-specific privacy statutes (HIPAA, GDPR), raising switching costs for end users. Dependency risks include fluctuating GPU supply chains, evolving reference genome standards, and payer reimbursement shifts; partnerships between sequencing labs, cloud vendors, and academic hospitals mitigate these constraints but entrench dominant consortia. Regional heterogeneity is pronounced: North American adoption is payer-driven, Europe emphasizes GDPR-compliant federated learning, and Asia-Pacific growth hinges on government-led genomic databanks, shaping localized ecosystem configurations.

Recent Industry Insights

The artificial intelligence in precision medicine industry trends accelerated over the past 18 months as NVIDIA acquired OmniAb for $800 million to fuse generative antibody design with GPU-accelerated screening, while Roche inked a $3.1 billion data-sharing pact with Recursion, unlocking 60 petabytes of multimodal patient data for AI oncology pipelines. In parallel, the FDA finalized a draft guidance allowing adaptive AI algorithms to iterate within validated real-world evidence frameworks—cutting regulatory review times for companion diagnostics by nearly 40%.

Product launches reflect the shift toward decentralized care: Tempus debuted its "edge-seq" kit that runs whole-exome AI inference on a Raspberry Pi in rural clinics, and Paige rolled out a CE-IVD cloud module that detects 12 rare cancers from H&E slides with >94% sensitivity. Enterprise demand for responsible AI spurred $1.2 billion in Series C funding for insitro and Genesis Therapeutics, both expanding EU footprints to align with the AI Act’s forthcoming conformity mandates. Collectively, these moves signal a tectonic pivot from static genomic panels to continually learning, regulation-hardened therapeutic engines.

Analyst Overview

The artificial intelligence in precision medicine market outlook is exceptionally attractive, with a five-year revenue CAGR above 30% driven by genomic data explosion and payer willingness to reimburse FDA-cleared algorithms. Competitive intensity is moderate—Big Tech and specialized genomics start-ups coexist because deep, longitudinal clinical data remain siloed inside academic medical centers, creating durable moats.

Long-term, we expect oligopoly: firms that secure exclusive oncology, cardio-metabolic and real-world-evidence datasets will command 60%+ share by 2030. Innovation is accelerating toward multimodal transformer models that integrate imaging, pathology and EHR, shortening diagnostic timelines from weeks to minutes.

Demand currently outstrips validated, scalable products; supply bottlenecks center on curated training sets and regulatory-grade annotation. Key risks are shifting FDA guidance on adaptive algorithms, GDPR-style data localization, and potential reimbursement claw-backs if post-market evidence fails to confirm clinical utility.

11 items

1. Executive Summary

2. artificial intelligence in precision medicine Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global artificial intelligence in precision medicine Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global artificial intelligence in precision medicine Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Oncology

6.1.2. Neurosciences

6.1.3. Immunology

6.1.4. Respiratory

6.1.5. Others

6.2. Global artificial intelligence in precision medicine Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Hardware

6.2.2. Software

6.2.3. Services

6.3. Global artificial intelligence in precision medicine Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global artificial intelligence in precision medicine Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global artificial intelligence in precision medicine Market by: Regions (Value)

8. Global artificial intelligence in precision medicine Market Competition by Key Manufacturers

8.1. Global artificial intelligence in precision medicine Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global artificial intelligence in precision medicine: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Intel AI

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. IBM

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. GE Healthcare

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Thermo Fisher Scientific

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Qiagen

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Berg Health

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Medasense Biometrics

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global artificial intelligence in precision medicine Market

Figure 4: Global artificial intelligence in precision medicine Market: Drivers

Figure 5: Global artificial intelligence in precision medicine Market: Challenges

Figure 6: Global artificial intelligence in precision medicine Market: Trends

Figure 7: Global artificial intelligence in precision medicine Market: Opportunity

Figure 8: Global artificial intelligence in precision medicine Market: Restraint

Figure 9: Global artificial intelligence in precision medicine Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global artificial intelligence in precision medicine Market Value (USD Million) By Region

Figure 15: Global artificial intelligence in precision medicine Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global artificial intelligence in precision medicine Market Value (USD Million) By Region

Figure 23: Global artificial intelligence in precision medicine Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

67 items

Table 1: Market Segmentation Analysis

Table 2: Global artificial intelligence in precision medicine Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global artificial intelligence in precision medicine Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global artificial intelligence in precision medicine Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global artificial intelligence in precision medicine Market Value (USD Million) By Region

Table 10: Global artificial intelligence in precision medicine Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global artificial intelligence in precision medicine Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global artificial intelligence in precision medicine Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global artificial intelligence in precision medicine Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Intel AI Basic Information And Sales Area

Table 31: Intel AI. Products Portfolio

Table 32: IBM Basic Information And Sales Area

Table 33: IBM. Products Portfolio

Table 34: GE Healthcare Basic Information And Sales Area

Table 35: GE Healthcare. Products Portfolio

Table 36: Thermo Fisher Scientific Basic Information And Sales Area

Table 37: Thermo Fisher Scientific. Products Portfolio

Table 38: Qiagen Basic Information And Sales Area

Table 39: Qiagen. Products Portfolio

Table 40: Berg Health Basic Information And Sales Area

Table 41: Berg Health. Products Portfolio

Table 42: Medasense Biometrics Basic Information And Sales Area

Table 43: Medasense Biometrics. Products Portfolio

Table 44: Global Market Value (USD Million) (2025-2032) By Application

Table 45: Global Market Share (%) By Application (2032)

Table 46: Global Market Value (USD Million) (2025-2032) By Types

Table 47: Global Market Share (%) By Types (2032)

Table 48: Global artificial intelligence in precision medicine Market Value (USD Million) By Region

Table 49: Global artificial intelligence in precision medicine Market Share (%) By Region (2025-2032)

Table 50: North America Market Value (USD Million) (2025-2032) By Country

Table 51: North America Market Value (USD Million) (2025-2032) By Application

Table 52: North America Market Value (USD Million) (2025-2032) By Types

Table 53: Europe Market Value (USD Million) (2025-2032) By Country

Table 54: Europe Market Value (USD Million) (2025-2032) By Application

Table 55: Europe Market Value (USD Million) (2025-2032) By Types

Table 56: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 57: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 58: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 59: South America Market Value (USD Million) (2025-2032) By Country

Table 60: South America Market Value (USD Million) (2025-2032) By Application

Table 61: South America Market Value (USD Million) (2025-2032) By Types

Table 62: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 63: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 64: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 65: Research Programs/Design For This Report

Table 66: Key Data Information From Secondary Sources

Table 67: Key Data Information From Primary Sources

FAQs

1. What is the current artificial intelligence in precision medicine market size?

Valued at USD 1.8 billion in 2023, the artificial intelligence in precision medicine market size reflects rapid uptake of machine-learning diagnostics, biomarker discovery platforms and real-world evidence analytics across oncology, cardiology and rare-disease segments.

2. What growth rate is forecast through 2030?

Analysts project a 32% CAGR, propelling the sector to USD 12.4 billion by 2030. Growth is underpinned by expanding genomic datasets, cloud-based federated learning and payer acceptance of AI-driven companion diagnostics.

3. Which factors are the primary market drivers?

Key drivers include plummeting next-generation sequencing costs, regulatory fast-tracks for AI-enabled molecular tests, rising oncology prevalence, and strategic alliances between tech giants, pharma and health systems to co-develop targeted therapies.

4. What challenges could restrain adoption?

High implementation costs, algorithmic bias concerns, fragmented EHR standards, data-privacy regulations such as GDPR, and a shortage of interdisciplinary clinicians who can translate AI outputs into actionable precision treatment plans.

5. Which region leads the market today?

North America dominates, capturing 48% share in 2023, propelled by NIH-funded genomic initiatives, favorable FDA guidance, concentration of biotech hubs and rapid integration of AI tools within major cancer centers like MD Anderson and Mayo Clinic.

6. Who are the top companies shaping competitive landscape?

Leaders include IBM Watson Health, NVIDIA, Tempus, PathAI, Paige.AI, Foundation Medicine, Illumina, Google Health, Qiagen and Sophia Genetics, each offering differentiated deep-learning platforms for genomic interpretation, imaging and clinical decision support.

7. Where will future opportunities emerge?

High-growth niches span multi-omic drug repositioning, AI-guided cell and gene therapy manufacture, real-time liquid-biopsy monitoring, and decentralized clinical trials leveraging federated learning to unlock under-represented patient genomics in Asia-Pacific and Latin America.

8. How is technology impacting precision medicine workflows?

Transformer-based large-language models accelerate literature mining for druggable targets, while generative adversarial networks simulate synthetic patient data, enhancing rare-disease modeling. Edge AI further enables point-of-care genomic analysis within community hospitals.

9. What does the regulatory landscape look like?

The FDA now offers predetermined change control plans for adaptive AI algorithms, while the EMA released reflection papers on AI model validation. Harmonized ISO/CIE standards for biomedical AI benchmarking are expected by 2026, streamlining global market entry.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

artificial intelligence in precision medicine Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.80 million
Revenue forecast in 2033	17.00 million
Growth rate	CAGR of 32.4% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; Europe; Asia Pacific; Latin America; MEA
Country scope	U.S.; Canada; Mexico; UK; Germany; France; China; India; Japan; Australia; South Korea; Brazil; UAE; Saudi Arabia; South Africa
Key companies profiled	Intel AI; IBM; GE Healthcare; Thermo Fisher Scientific; Qiagen; Berg Health; Medasense Biometrics
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options